Trial reportBritish journal of clinical pharmacology2009
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
Trial report in British journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 60 citations in OpenAlex.
- The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.PloS one · 2012Trial
- Clinical symptoms and neuroanatomical substrates of daytime sleepiness in Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Anticholinergic burden and revisit risk in frail patients with pharmacological sleepiness.European journal of hospital pharmacy : science and practice · 2024Article
- Prediction of Quality of Life in Patients With Parkinson's Disease With and Without Excessive Daytime Sleepiness: A Longitudinal Study.Frontiers in aging neuroscience · 2022Article
- An Update on Assessment, Therapeutic Management, and Patents on Insomnia.BioMed research international · 2021Review
- Review
- Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease.Disease models & mechanisms · 2016Article
- Pramipexole Impairs Stimulus-Response Learning in Healthy Young Adults.Frontiers in neuroscience · 2016Article
- Sleep spindle alterations in patients with Parkinson's disease.Frontiers in human neuroscience · 2015Article
- Potentially driver-impairing (PDI) medication use in medically impaired adults referred for driving evaluation.The Annals of pharmacotherapy · 2014Article
- Medications and impaired driving.The Annals of pharmacotherapy · 2014Review
- Dopaminergic role in regulating neurophysiological markers of sleep homeostasis in humans.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.Movement disorders : official journal of the Movement Disorder Society · 2012Article
- Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?Therapeutic advances in neurological disorders · 2012Article
- Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.CNS drugs · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess the sleepiness induced by pramipexole, a D2/D3-dopamine receptor agonist commonly used in Parkinson's disease and restless legs syndrome, without the problem of the confounding factors related to the disease.
methodsPlacebo, bromocriptine (2.5 mg), L-dopa (100 mg) and pramipexole (0.5 mg) were administered in a single oral dose on four separate days, with at least a 2-week wash-out period in a randomized cross-over design. Induced somnolence was assessed using Multiple Sleep Latency Test (MSLT) and subjective scaling of vigilance. Twelve male subjects (26.3 +/- 5.5 years old) without anxiety, mood, sleep or sedation disorders were enrolled.
resultsPramipexole significantly reduced mean sleep latency compared with placebo 3 h 30 min [-6.1 min (-9.8, -2.4), P = 0.002] and 5 h 30 min [-5.6 min (-7.7, -3.5), P = 0.003] after administration. In addition, the total duration of sleep during the tests was higher with pramipexole than with placebo [+6.0 min (2.3, 9.7), P < 0.001]. These differences were not observed with L-dopa and bromocriptine in comparison with placebo. The induced sleepiness was not associated with an increase in subjective somnolence scaling, indicating that this adverse event may occur without prior warning.
conclusionsThese results show that a single oral dose of pramipexole induces sleepiness as assessed by MSLT in healthy young subjects, independent of disease-related sleep dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.